异动分析 代糖概念+参股银行+人民币贬值受益+专精特新+海峡两岸 1、公司生产的健康甜味剂产品主要为阿洛酮糖，阿洛酮糖是在自然界中天然存在但含量极少的一种稀 有单糖，其甜味及口感与蔗糖相当类似或接近，但其热量却远低于蔗糖，对于肥胖以及糖尿病患者是一 种理想的蔗糖代替物。 2、2024年半年报，公司持有山东禹城农村商业银行股份有限公司 5.14%股份。 3、根据2024年年报，公司海外营收占比为60.62%，受益于人民币贬值。 4、专精特新"小巨人"企业是全国中小企业评定工作中最高等级、最具权威的荣誉称号，是指专注于细 分市场、创新能力强、市场占有率高、掌握关键核心技术、质量效益优的排头兵企业，对于提升中小企 业自身的竞争力，以及提升产业链、供应链稳定性和竞争力具有重大意义。公司已入选工信部专精特新 小巨人企业名单。 来源：新浪证券-红岸工作室 2月24日，百龙创园跌0.12%，成交额1.78亿元，换手率1.71%，总市值103.62亿元。 主力没有控盘，筹码分布非常分散，主力成交额5348.55万，占总成交额的9.62%。 5、根据2023年4月28日公告：公司作为全球重要的益生元和膳食纤维产品生产商，产品远 ...

Core Viewpoint - The company plans to establish a wholly-owned subsidiary in Nanjing with an investment of 10 million RMB to enhance its international market presence and boost export revenue [1] Group 1 - The company will set up a subsidiary named Bailong Chuangyuan (Nanjing) Biotechnology Co., Ltd. with a registered capital of 10 million RMB [1] - The investment aims to strengthen the overseas sales team and actively explore international markets [1] - The initiative is expected to improve the company's export business income and overall profitability [1]

Core Viewpoint - The company, Bailong Chuangyuan, announced the establishment of a wholly-owned subsidiary, Bailong Chuangyuan (Nanjing) Biotechnology Co., Ltd., with an investment of 10 million RMB to enhance its international market presence and sales team [1] Group 1 - The investment aims to strengthen the overseas sales team and actively explore international markets [1] - The establishment of the Nanjing subsidiary will facilitate the recruitment of international trade talent and leverage Nanjing's geographical advantages to expand overseas customer outreach and technical exchanges [1] - This initiative is expected to increase the company's export revenue and enhance its service capabilities for overseas clients, thereby improving overall profitability [1]

Group 1 - The core point of the article is that Bailong Chuangyuan (605016) reported a total of 15,685 shareholders as of February 10, 2026 [1]

证券代码：605016 证券简称：百龙创园 公告编号：2026-002 山东百龙创园生物科技股份有限公司 关于对外投资设立南京全资子公司的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●投资标的名称：百龙创园（南京）生物科技有限公司 ●投资金额：1,000 万元人民币，占注册资本的 100%。 ●相关风险提示：本次对外投资是从公司长远利益出发做出的慎重决策，但仍存 在因政策、市场、管理等各方面不确定因素带来的风险。敬请广大投资者注意投资风险， 谨慎投资。 一、对外投资概述 （一）对外投资的基本情况 山东百龙创园生物科技股份有限公司（以下简称"公司"）基于发展战略规划及 经营发展需要，以自有资金 1,000 万元人民币，在南京投资设立全资子公司百龙创园 （南京）生物科技有限公司（以下简称"南京百龙"），公司直接持有南京百龙 100%的股份。 根据《山东百龙创园生物科技股份有限公司章程》《对外投资管理制度》的相关 规定，本次设立全资子公司事宜无需提交公司董事会、股东会批准。 投资主要目的：加强海外销售 ...

Group 1 - The company, Bailong Chuangyuan (605016.SH), announced the establishment of a wholly-owned subsidiary, Bailong Chuangyuan (Nanjing) Biotechnology Co., Ltd. (referred to as "Nanjing Bailong") [1] - The investment in Nanjing Bailong amounts to 10 million yuan, funded by the company's own resources [1] - The company holds 100% ownership of Nanjing Bailong [1]

Group 1 - The company, Bailong Chuangyuan (605016), announced the establishment of a wholly-owned subsidiary, Bailong Chuangyuan (Nanjing) Biotechnology Co., Ltd., in Nanjing [1] - The investment amount for this new subsidiary is 10 million yuan, funded by the company's own resources [1] - The company will hold 100% ownership of the newly established subsidiary [1]

Core Viewpoint - The company, Bailong Chuangyuan (605016.SH), has announced the establishment of a wholly-owned subsidiary, Bailong Chuangyuan (Nanjing) Biotechnology Co., Ltd., with an investment of 10 million RMB to enhance its international market presence and sales team [1] Group 1 - The investment aims to strengthen the overseas sales team and actively explore international markets [1] - The company will leverage Nanjing's geographical advantages to expand overseas customer development and technical exchanges [1] - This initiative is expected to increase the company's export revenue and enhance its overall profitability and overseas customer service capabilities [1]

Core Viewpoint - The company, Bailong Chuangyuan (605016.SH), has announced the establishment of a wholly-owned subsidiary, Bailong Chuangyuan (Nanjing) Biotechnology Co., Ltd., with an investment of 10 million RMB to enhance its international market presence and sales team [1] Group 1: Investment and Strategic Development - The investment of 10 million RMB is aimed at strengthening the overseas sales team and actively exploring international markets [1] - The company will leverage the geographical advantages of Nanjing to expand its overseas customer base and enhance technical exchanges [1] Group 2: Operational Impact - The establishment of the Nanjing subsidiary is expected to increase the company's export revenue and improve its overall profitability by enhancing overseas customer service capabilities [1]

Core Viewpoint - The company is establishing a wholly-owned subsidiary, Bailong Chuangyuan (Nanjing) Biotechnology Co., Ltd., with an investment of 10 million RMB to enhance its international trade capabilities and improve overall profitability [1] Group 1: Company Strategy - The establishment of the Nanjing subsidiary aligns with the company's strategic development plan and operational needs [1] - The company will focus on recruiting international trade talent to leverage Nanjing's geographical advantages [1] Group 2: Business Development - The new subsidiary aims to expand overseas customer development and technical exchanges [1] - This initiative is expected to increase the company's export revenue and enhance its service capabilities for overseas clients [1]